New Zealand markets closed

ImmunoPrecise Antibodies Ltd. (IPA)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
5.35-0.31 (-5.48%)
At close: 04:00PM EST
Currency in USD

Valuation measures4

Market cap (intra-day) 105.15M
Enterprise value 76.02M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)6.61
Price/book (mrq)2.46
Enterprise value/revenue 4.06
Enterprise value/EBITDA -8.78

Trading information

Stock price history

Beta (5Y monthly) -0.16
52-week change 3-63.60%
S&P500 52-week change 317.58%
52-week high 319.00
52-week low 35.03
50-day moving average 35.77
200-day moving average 36.82

Share statistics

Avg vol (3-month) 350.76k
Avg vol (10-day) 336.14k
Shares outstanding 519.43M
Implied shares outstanding 6N/A
Float 818.04M
% held by insiders 17.06%
% held by institutions 16.76%
Shares short (30 Dec 2021) 4310.25k
Short ratio (30 Dec 2021) 45.98
Short % of float (30 Dec 2021) 4N/A
Short % of shares outstanding (30 Dec 2021) 41.60%
Shares short (prior month 29 Nov 2021) 4318.52k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 322 Nov 2020
Ex-dividend date 4N/A
Last split factor 21:5
Last split date 322 Nov 2020

Financial highlights

Currency in CAD.

Fiscal year

Fiscal year ends 29 Apr 2021
Most-recent quarter (mrq)30 Oct 2021


Profit margin -77.89%
Operating margin (ttm)-63.35%

Management effectiveness

Return on assets (ttm)-14.24%
Return on equity (ttm)-35.54%

Income statement

Revenue (ttm)18.7M
Revenue per share (ttm)1.01
Quarterly revenue growth (yoy)-0.70%
Gross profit (ttm)11.4M
EBITDA -10.59M
Net income avi to common (ttm)-14.57M
Diluted EPS (ttm)-0.62
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)38.36M
Total cash per share (mrq)1.97
Total debt (mrq)2.93M
Total debt/equity (mrq)5.75
Current ratio (mrq)5.84
Book value per share (mrq)2.63

Cash flow statement

Operating cash flow (ttm)-4.43M
Levered free cash flow (ttm)-1.22M